GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
- Durable improvements observed in visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile - - Recent FDA interactions clarify clinically meaningful improvement on microperimetry and no further comments or questions regarding the company’s pre-clinical or CMC
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness , announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus
- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group - - Data from Group 5 supports use of higher dose level in Phase 2/3
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
